1. Fitbit Usage in Patients With Breast Cancer Undergoing Chemotherapy.
- Author
-
Dreher N, Hadeler EK, Hartman SJ, Wong EC, Acerbi I, Rugo HS, Majure MC, Chien AJ, Esserman LJ, and Melisko ME
- Subjects
- Adult, Aged, Breast Neoplasms drug therapy, Breast Neoplasms metabolism, Breast Neoplasms pathology, Chemotherapy, Adjuvant, Female, Follow-Up Studies, Humans, Middle Aged, Neoadjuvant Therapy, Pilot Projects, Prognosis, Receptor, ErbB-2 metabolism, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism, Surveys and Questionnaires, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms rehabilitation, Exercise, Fitness Trackers statistics & numerical data, Monitoring, Physiologic
- Abstract
Background: Many patients' activity levels decrease during chemotherapy. Wearable devices, such as Fitbits, track activity patterns and may encourage behavior change. This study aimed to determine the utility of using Fitbits to measure physical activity and sleep throughout chemotherapy., Patients and Methods: Patients with early stage breast cancer were enrolled prior to starting chemotherapy. Patients received a Fitbit Charge HR and were instructed to wear it and sync at least weekly throughout chemotherapy and up to 6 months post therapy. Patients completed baseline surveys, and treatment information was collected from their medical records. Fitbit data was downloaded from the Fitabase data management platform. To assess utility, we evaluated how many days patients wore their Fitbit for at least 10 hours., Results: Adherence to wearing the Fitbit was low, with 16.9% of patients never syncing their device. For those who did sync, the mean number of valid days (> 10 hours of use) across the 9-month study period was 44.5% (SD, 36.9%), and the median was 39.6%, with a range of 0% to 100% of the total study days. Adherence was higher among participants receiving adjuvant chemotherapy versus neoadjuvant chemotherapy (51.9% vs. 29.6% valid days, respectively [P = .037]). Baseline questions indicating positive attitudes toward technology were significantly correlated with higher adherence., Conclusions: Fitbit use during breast cancer chemotherapy was poor in the absence of prompts to encourage wear. Interventions including phone calls, texts, or other reminders to maintain adherence are likely necessary to increase wear in active treatment settings., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF